1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends

Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2022 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline

  • December 2016
  • 110 pages
  • GBI Research
Report ID: 3172450

Summary

Table of Contents

Search Inside

Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2022 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline

Summary
Hypertension is a serious and common medical condition characterized by elevated blood pressure. It is commonly seen in the aging population, and in people with sedentary lifestyles and obesity. As one of the most significant preventable causes of death worldwide, early diagnosis of the condition is crucial to improve health outcomes. Hypertension is the key risk factor for stroke; according to the National Stroke Association (NSA), two-thirds of patients who suffer a stroke have hypertension.

The anti-hypertensive therapeutics market is expected to grow significantly over the forecast period across the five Asia-Pacific (APAC) markets, from $19.1 Billion in 2015 to $27 Billion by 2022, at a compound annual growth rate (CAGR) of 5.1%. This growth is primarily attributed to the increasingly elderly population – where the prevalence rate of hypertension is at the highest – and increases in risk factors such as being overweight or obese, high daily sodium intake, low physical activity levels, urbanization, consumption of alcohol, smoking, and mental stress. In the five assessed APAC countries, the total population aged 65 and over was 1 Billion in 2015, and this is expected to grow at a CAGR of 3.32% to reach 1.2 Billion in 2022 (US Census Bureau, 2016).

The antihypertensive pipeline consists of 112 pipeline products, most of which are small molecules. Most of the pipeline products are at early stages of development, with Discovery and Preclinical products accounting for 55%. Phase I, II and III products account for 40%, and Pre-registration products account for 4%.

In the five assessed APAC regions, the total estimated prevalence population of hypertension was approximately 548 million in 2015. Of these, approximately 335 million (61.1%) were undiagnosed. Moreover, among the diagnosed patients, approximately 104.7 million (49.1%) were untreated, while 108.5 million (50.9%) were treated with drug therapy. The low diagnosis and treatment rates are primarily due to the lack of awareness of the condition among healthcare professionals, patients, and the public. The asymptomatic nature of the disease is another major factor limiting the diagnosis rate, and a lack of frequent blood pressure checks due to limited affordability and healthcare accessibility in countries such as India and China is another contributing factor.

Moreover, two major marketed products, Benicar/Olmetec (olmesartan medoxomil), and Rasilez (aliskiren), are expected to see their patents expire in Japan and Australia during the forecast period. The patent of Olmetec is expected to expire in Japan in 2016 and Australia in 2017, while the patent of Rasilez (aliskiren) is expected to expire in Australia in 2020. Increasing generic competition across the five APAC regions will restrict market growth during the forecast period.

The report “Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2022 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline” provides an introduction to anti-hypertensive, detailing the epidemiology, etiology, diagnostic techniques, pathophysiology, disease staging and prognoses for patients.

In depth, it provides the following -
- Detailed analysis of the drugs currently marketed for anti-hypertensive (Cozaar, Benicar, Micardis, Diovan, Azilva, Norvasc, Rasilez, Tritace, Carvedilol, Prestalia, Exforge).
- Provides detailed analysis of the pipeline for anti-hypertensive, by stage of development, molecule type, program type, mechanism of action and molecular target.
- Detailed analysis of recent clinical trials in this indication, by enrollment, duration and failure rate. Promising late-stage pipeline molecules are analyzed and assessed in terms of their potential competitive strength.
- Supplies forecasts for the anti-hypertensive markets, including epidemiology, treatment usage patterns, pricing and market size for the 2015–2022 period. The five APAC markets are covered, and data are presented at a country level.
- Detailed analysis of the key market drivers and barriers for the anti-hypertensive markets.
- Describes the major deals that have taken place in the global anti-hypertensive markets in recent years. This coverage analyzes licensing and co-development agreements, segmented by stage of development, year, molecule type, mechanism of action and value.

Scope
The Asia-Pacific antihypertensive market will be valued at $27 billion in 2022, growing from $19.1 billion in 2015 at a CAGR of 5.1%. Hypertension prevalence is a prominent contributor to market size in the assessed countries. The market is mostly dominated by generics, and there are only a few patented products.
- Will generics continue to dominate treatment?
- How do the elderly populations and their associated risk factors affect prevalence?
- What effect will the patent expirations of currently branded therapies have on market value?
The current anti-hypertensive therapeutics pipeline is weak, comprising 112 molecules in various stages of development, dominated by small molecules.
- Which molecular targets appear most frequently in the pipeline?
- Is there potential for the pipeline to address unmet needs within the anti-hypertensive market?
Analysis of clinical trials since 2006 identified that anti-hypertensive products have a high rate of attrition.
- How do failure rates vary by product stage of development, molecule type, and mechanism of action?
- How do other factors such as average trial duration and trial size influence the costs and risks associated with product development?
The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value, due to the high annual cost of therapy. Growth in market size is projected to vary considerably across the five assessed markets.
- How will the annual cost of therapy and market size vary between the five Asia-Pacific markets?
- How could changes in risk factors such as aging population, metabolic disorders and high salt intake influence the market?
- Various drivers and barriers will influence the market over the forecast period.
- What are the barriers that limit the uptake of premium-priced therapeutics in the assessed countries?
- Which factors are most likely to drive the market in these countries?

Reasons to buy
This report will allow you to -
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
- Visualize the composition of the anti-hypertensive market in terms of the dominant therapies, and their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
- Analyze the anti-hypertensive pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
- Consider market opportunities and potential risks by examining trends in hypertension clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action.
- Predict anti-hypertensive market growth in the five Asia-Pacific markets with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.
- Identify commercial opportunities in the anti-hypertensive deals landscape by analyzing trends in licensing and co-development deals.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Global Acute Ischemic Stroke Therapeutics Market 2017-2021

  • $ 3500
  • Industry report
  • August 2017
  • by Infiniti Research Limited

About Acute Ischemic Stroke Therapeutics AIS is a chronic condition characterized by the sudden loss of blood supply to a part of the brain, thus causing subsequent loss of neurological function. AIS is ...

Cardiovascular Drugs Industry Forecasts - China Focus

  • $ 1800
  • Industry report
  • March 2017
  • by Asia Market Information & Development Company

This study focuses on China’s Cardiovascular Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities ...

Global Respiratory Complications Therapeutics Market to 2022 - Innovative Pneumonia and Pulmonary Arterial Hypertension Therapies Dominate Varied Disease Market

  • $ 4995
  • Industry report
  • March 2017
  • by GBI Research

Global Respiratory Complications Therapeutics Market to 2022 - Innovative Pneumonia and Pulmonary Arterial Hypertension Therapies Dominate Varied Disease Market Summary Respiratory complications are a ...

The Generic Injectables Market

February 2017 $ 3850

ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.